Could a diabetes drug help detect Alzheimer's early?
NCT ID NCT03560960
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether a single injection of pramlintide, a diabetes drug, can temporarily increase levels of Alzheimer's-related proteins in the blood, potentially revealing early signs of the disease. Researchers will measure changes in beta-amyloid and tau proteins before and after injection in 57 people with mild cognitive impairment, Alzheimer's, or normal cognition. The goal is to develop a simple, accessible blood test for early Alzheimer's detection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pramlintide (Symlin)
What this could lead to
If successful, this could lead to a simple blood test for early Alzheimer's detection, helping diagnose the disease before severe symptoms appear.
What could go wrong
This is a very early, small study (57 people) testing a biomarker, not a treatment. The approach may not reliably distinguish early Alzheimer's from other conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BU Alzheimer Disease Center
Boston, Massachusetts, 02118, United States
-
Indiana University Alzheimer Disease Center
Indianapolis, Indiana, 46202, United States
-
Memory Center VA Boston Healthcare
Jamaica Plain, Massachusetts, 02130, United States